Sequential regional cerebral blood flow brain scans using PET with H215O demonstrate ketamine actions in CNS dynamically

Neuropsychopharmacology

Volumn 25, Issue 2, 2001, Pages 165-172

  Holcomb, Henry H ^a   Lahti, Adrienne C ^a   Medoff, Deborah R ^a   Weiler, Martin ^a   Tamminga, Carol A ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Ketamine; Pharmacodynamics; rCBF, functional imaging

Indexed keywords

KETAMINE; PLACEBO; PSYCHEDELIC AGENT; WATER O 15;

ADULT; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR; BRAIN BLOOD FLOW; BRAIN REGION; BRAIN SCINTISCANNING; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; FEMALE; FLOW RATE; HUMAN; MALE; NORMAL HUMAN; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ADULT; ANESTHETICS, DISSOCIATIVE; AREA UNDER CURVE; BRAIN; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; KETAMINE; MALE; OXYGEN RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034984928     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00229-9     Document Type: Article

References (24)

1. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers
2. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: Differences between normal controls and schizophrenic patients
3. Visualisation of changes in regional cerebral blood flow (rCBF) produced by ketamine using long TE gradient-echo sequences: Preliminary results
4. Ketamine effects on local cerebral blood flow and metabolism in the rat
5. Analysis of functional MRI time-series
6. Assessing the significance of focal activations using their spatial extent
7. Anatomy and physiology of glutamate in the CNS
8. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol
9. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
10. Ketamine activates psychosis and alters limbic blood flow in schizophrenia
11. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
12. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers
13. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors
14. Regional variations in the pharmacology of NMDA receptor channel blockers: Implications for therapeutic potential
15. Agonist response kinetics of N-methyl-D-aspartate receptors in neurons cultured from rat cerebral cortex and cerebellum: Evidence for receptor heterogeneity
16. Schizophrenia and glutamatergic transmission
17. PCP-induced alterations in cerebral glucose utilization in rat brain: Blockade by metaphit, a PCP-receptor-acylating agent
18. Neuroleptic plasma levels
19. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)
20. Alterations in local cerebral glucose utilization induced by phencyclidine
21. Neuroexcitation, excitotoxicity and human neurological disease
22. Ketamine - Its pharmacology and therapeutic uses